Updated news of medical treatments to Amyotrophic Lateral Sclerosis (ALS)

By | November 18, 2014

For the ALS patients, the only hope is that the progress of the ongoing researches can catch up with the development their  “ALS”. Here I collect and will update the news of the therapies in the world to Amyotrophic Lateral Sclerosis (ALS).

May 5, 2015

Mayo Clinic: New Mouse Model for ALS and Frontotemporal Dementia Gene Offers Hope for Potential Therapies

Pictured are nuclei (blue) of neurons in the ALS/FTD mouse model showing they contain inclusions of both RNA (left panel, red) or poly(GA) protein (right panel, red) and TDP-43 (both panels, green).
Pictured are nuclei (blue) of neurons in the ALS/FTD mouse model showing they contain inclusions of both RNA (left panel, red) or poly(GA) protein (right panel, red) and TDP-43 (both panels, green).
JACKSONVILLE, Fla. — Researchers at Mayo Clinic in Florida have developed a mouse model that exhibits the neuropathological and behavioral features associated with the most common genetic form of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) and frontotemporal dementia (FTD), which are caused by a mutation in the C9ORF72 gene.

They say their findings, reported today in Science, will speed further research into the molecular mechanism behind these disorders and that the animal model will offer a way to test potential therapeutic agents to halt the death of neurons in the brain and spinal cord.

More details, please visit: http://newsnetwork.mayoclinic.org/discussion/mayo-clinic-new-mouse-model-for-als-and-frontotemporal-dementia-gene-offers-hope-for-potential-therapies/.


May 5, 2015

Progress in Drug Development Reviewed at The ALS Association Drug Company Working Group Meeting

News about a new drug, a new delivery method, a new trial, and a new approach to working with the Food and Drug Administration (FDA) were the highlights of The ALS Association’s annual Drug Company Working Group meeting, held in April in Washington, D.C., in conjunction with the American Academy of Neurology (AAN) Meeting.

ALS is a progressive neurodegenerative disease that affects neurons (nerve cells) in the brain and the spinal cord. Eventually, people with ALS lose the ability to initiate and control muscle movement, which often leads to total paralysis and death within two-to-five years of diagnosis. There is no cure and no life-prolonging treatments for the disease.

“This meeting is an important opportunity for those working in ALS drug development, and those who are interested in getting into the field, to learn about progress and share new approaches,” said Lucie Bruijn, Ph.D., M.B.A., Chief Scientist for The ALS Association.

More details, please visit http://www.alsa.org/news/media/press-releases/progress-in-drug-development.html.


November 13, 2014

November 13, 2014 – BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three and nine months ending September 30, 2014.

Tony Fiorino, MD, PhD, Chief Executive Officer of BrainStorm, commented, “The third quarter was extremely productive from a clinical as well as operational perspective. We added a second site to our phase 2 ALS study and received FDA clearance for manufacturing at our third site, and enrollment has moved along as planned. Also in the quarter, the FDA granted Fast Track designation to NurOwn™ in ALS, which will allow us to work with the FDA toward approval of our therapy in the most expeditious manner possible. In Israel, we had the last follow-up visit for the last subject enrolled in our phase 2a ALS trial at Hadassah, and we are now analyzing the full data set. Finally, we have begun to design a multi-dose study of NurOwn™ that will allow us to gain very important safety and efficacy data for both multiple doses and for the use of frozen cells.” Dr. Fiorino continued, “On top of these important clinical developments, we had a successful uplisting to NASDAQ during the quarter, which we believe we will bring broadened awareness of BrainStorm’s progress and potential that will translate into improved liquidity and access to a broader investor base.”

More details, please visit http://www.brainstorm-cell.com/index.php/news-events/328-november-13-2014.


October 6, 2014

BrainStorm Reports Last Patient Visit in Phase 2a ALS Study

“I am pleased to bring this second study of NurOwn™ to a successful conclusion,” added Professor Karussis.  “I have now treated over 30 ALS patients with NurOwn™ in two clinical trials, as well as in several compassionate use treatments, and I am enthusiastic about its emerging safety and efficacy profile.”

More details, please go to http://www.brainstorm-cell.com/index.php/news-events/325-october-6-2014


August 18, 2014

BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Mayo Clinic Human Cellular Therapy Laboratory in Rochester, Minn. for production of NurOwn™, BrainStorm’s proprietary autologous mesenchymal stem cells secreting neurotrophic factors (MSC-NTF). BrainStorm will continue working with the Mayo clinical team to complete the necessary steps to allow the site to begin enrolling subjects into its ongoing phase 2 study of NurOwn™, which is designed to evaluate the safety and efficacy of the transplantation of or NurOwn™ in patients with Amyotrophic Lateral Sclerosis (ALS).

More details, please go to http://www.brainstorm-cell.com/index.php/news-a-events/315-august-18-2014